Neuphoria Therapeutics Inc (NASDAQ: NEUP) is a clinical-stage biotechnology company focused on developing pharmaceutical product candidates. The company generates no product revenue, funding operations through equity issuances including an at-the-market (ATM) facility and ADS share offerings, as disclosed in its 10-K filed September 29, 2025. As of June 30, 2025, Neuphoria employed seven full-time employees, one part-time employee, and sixteen part-time consultants, reflecting its early-stage scale. The company carries no long-term debt or capital lease obligations but holds a long-term operating lease. Operations span at minimum the United States and Australia, based on regulatory compliance disclosures. CEO Spyridon Papapetropoulos, M.D., and CFO Timothy Cunningham signed the FY2025 annual filing. The company has accumulated losses and relies on external financing to fund clinical trials and research and development activities, with no disclosed timeline to profitability.

Revenue model

No product revenue as of FY2025 (fiscal year ended June 30, 2025). Operations are funded through equity issuances, including ADS share offerings and an ATM facility, as disclosed in the 10-K filed September 29, 2025.

Products and services

Clinical-stage pharmaceutical product candidates. Specific drug names, therapeutic areas, or pipeline stages are not identified in the provided filing excerpts.

Customers and end markets

No commercial customers disclosed. End markets are not specified in the provided filing excerpts. Regulatory disclosures reference Medicare Part D and potential EEA drug pricing frameworks, suggesting eventual target markets in the United States and European Economic Area.

Value-chain role

Early-stage drug developer operating upstream of commercialization. Relies on third-party consultants and contractors for development activities. No manufacturing, distribution, or commercial sales infrastructure disclosed.

Geographic exposure

Operations in at least the United States and Australia, based on regulatory compliance references in the 10-K filed September 29, 2025. Broader geographic footprint not specified in the provided excerpts.

Source: SEC 10-K, filed 2025-09-29

Industry: Pharmaceutical Preparations Peers: Kazia Therapeutics Ltd